Safinamide

TargetMol
Product Code: TAR-T6651L
Supplier: TargetMol
CodeSizePrice
TAR-T6651L-5mg5mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6651L-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6651L-10mg10mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6651L-25mg25mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6651L-50mg50mg£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6651L-100mg100mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6651L-500mg500mg£543.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Safinamide is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. Potential additional uses might be restless leg syndrome and epilepsy. Safinamide is a reversible and selective monoamine oxidase B inhibitor, reducing the degradation of dopamine, and a glutamate release inhibitor. It also inhibits dopamine reuptake. Safinamide also blocks sodium and calcium channels.
CAS:
133865-89-1
Formula:
C17H19FN2O2
Molecular Weight:
302.35
Pathway:
Metabolism|Neuroscience
Purity:
0.98
SMILES:
C[C@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C(N)=O
Target:
MAO

References

Perez-Lloret S, Rascol O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. Expert Rev Neurother. 2016;16(3):245-58. Cattaneo C, et al. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLE. J Parkinsons Dis. 2016;6(1):165-7 Stocchi F, Torti M. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. Drug Des Devel Ther. 2016 Feb 5;10:609-18. Rasheed MZ, Tabassum H, Parvez S. Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease. Protoplasma. 2016 Jan 29.